JWJunnan Wang

Junnan Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Junnan Wang has a total of 81 co-authors. Here are the top co-authors by number of shared publications:

  • Junduo Wu

    Department of Cardiology, Second Hospital of Jilin University, Changchun, Jilin 130041, China

    9 shared publications
  • Dandan Song

    Department of Clinical Laboratory, Second Hospital of Jilin University, No. 218 Ziqiang Street, Changchun 130041, China

    8 shared publications
  • Youyou Yan

    Department of Cardiology, Second Hospital of Jilin University, Changchun, Jilin, 130041, China

    8 shared publications
  • Chao Qi

    Department of Cardiology, Second Hospital of Jilin University, Changchun, Jilin 130041, China; Changbaishan Laboratory, Jilin University, Changchun 130012, China

    6 shared publications
  • Jia Liu

    Department of Cardiology, Second Affiliated Hospital of Jilin University, Changchun 130022, China

    6 shared publications
  • Zhenzhen Chen

    Department of Cardiology, Second Hospital of Jilin University, Changchun, Jilin 130041, China

    5 shared publications

Latest Publications

  • Open Access

    MAP4K4 inhibition enhances the anti-ferroptosis effect of the FTO/YAP/ATF4 axis in doxorubicin-induced cardiotoxicity

    by Youyou Yan, Dandan Song, Longbo Li, Junnan Wang

    Doxorubicin (DOX) is a highly effective chemotherapeutic agent, but its clinical application was constrained by irreversible cardiotoxicity. Increasing evidence indicates that ferroptosis is a central mechanism of DOX-induced cardiotoxicity (DIC). Both the m⁶A demethylase FTO and yes-associated protein (YAP) are found to suppress ferroptosis in DIC. Importantly, both YAP and its upstream negative regulator, MAP4K4, are potential targets of FTO. However, whether FTO regulates DOX-induced cardiac ferroptosis via the MAP4K4/YAP signaling axis remains unexplored. FTO and YAP expressions were analyzed in DOX-treated cardiac tissues and cardiomyocytes. The effect of FTO on ferroptosis, as well as on the expression of YAP, ATF4, and MAP4K4, was evaluated in DOX-treated mouse heart and cardiomyocytes using cardiac-specific FTO AAV delivery or lentiviral transfection. Pharmacological inhibition of YAP, ATF4, or MAP4K4 was further performed to investigate the underlying mechanisms. In addition, the m⁶A modifications of FTO on MAP4K4 and YAP transcripts were examined. FTO and YAP were significantly reduced in DOX-treated cardiac tissues and cardiomyocytes. FTO overexpression markedly attenuated DIC by inhibiting ferroptosis by enhancing YAP and ATF4 expressions. Inhibition of YAP or ATF4 significantly abolished the protective and anti-ferroptotic effects of FTO. FTO also increased MAP4K4 expression, whereas MAP4K4 inhibition further enhanced the anti-ferroptotic effects mediated by the FTO/YAP/ATF4 axis. Mechanistically, FTO promoted m⁶A demethylation of MAP4K4 and YAP transcripts and enhanced their mRNA stability. FTO protects against DIC by inhibiting ferroptosis via up-regulation of the YAP/ATF4 axis, and inhibition of MAP4K4 further enhances the FTO/YAP/ATF4-mediated cardioprotective and anti-ferroptotic effects.

  • Open Access

    The possible mechanism and research progress of ACE2 involved in cardiovascular injury caused by COVID-19: a review

    by Dan Luo, Mengzhe Bai, Wei Zhang, Junnan Wang

    ACE2 is the earliest receptor discovered to mediate the entry of SARS-CoV-2. In addition to the receptor, it also participates in complex pathological and physiological processes, including regulating the RAS system, apelin, KKS system, and immune system. In addition to affecting the respiratory system, viral infections also interact with cardiovascular diseases. SARS-CoV-2 can directly invade the cardiovascular system through ACE2; Similarly, cardiovascular diseases such as hypertension and coronary heart disease can affect ACE2 levels and exacerbate the disease, and ACE2 dysregulation may also be a potential mechanism for long-term acute sequelae of COVID-19. Since the SARS CoV-2 epidemic, many large population studies have tried to clarify the current focus of debate, that is, whether we should give COVID-19 patients ACEI and ARB drug treatment, but there is still no conclusive conclusion. We also discussed potential disease treatment options for ACE2 at present. Finally, we discussed the researchers’ latest findings on ACE2 and their prospects for future research.


  • Open Access

    Inhibiting microRNA-200a-3p attenuates pyroptosis via targeting the SIRT1/NF-κB/NLRP3 pathway in H2O2-induced HAEC

    by Jia Liu, Youyou Yan, Dongdong Zheng, Jifeng Zhang, Junnan Wang

    Atherosclerosis is a chronic inflammatory disease of the arterial wall caused by many factors. Endothelial cell dysfunction is the initial factor in the development of atherosclerosis, and ROS activates the assembly of inflammasomes and induces the pyroptosis of vascular endothelial cells. Whether H2O2 induced human aortic endothelial cells (HAECs) pyroptosis and the underlying mechanisms remain unclear. This study aimed to investigate the role of microRNA-200a-3p in H2O2-induced HAECs pyroptosis. First, we found that the pyroptosis-related protein was upregulated in aortia in HFD apoE-/- mice. The in vitro study showed that the activation of NLRP3 inflammasomes and the pyroptosis in H2O2-induced HAECs, which is characterized by an increase in Lactate dehydrogenase (LDH) activity, and an increase in propidium iodide (PI)-positive cells. The expression of silent information regulator of transcription 1 (SIRT1) was also decreased in H2O2-induced HAECs, and the overexpression of SIRT1 could reverse the occurrence of pyroptosis, partly through p65 deacetylation, thereby inhibiting nuclear translocation of p65 and regulating NLRP3 expression. Further studies revealed increased miRNA-200a-3p expression in H2O2-induced HAECs and the promotion of pyroptosis, which was achieved by targeting SIRT1. Inhibition of miR-200a-3p reduced pyroptosis by promoting the expression of the downstream target gene SIRT1 and reducing the accumulation of p65 and NLRP3. Collectively, our results suggest that H2O2 can regulate NLRP3 inflammasomes through the miR-200a-3p/SIRT1/NF-κB (p65) signaling pathway and promote HAEC pyroptosis. The miR-200a-3p inhibitor can promote the expression of SIRT1 and inhibit pyroptosis, which may be important to prevent and treat atherosclerosis.


  • Open Access

    m6A Methylation in Cardiovascular Diseases: From Mechanisms to Therapeutic Potential

    by Longbo Li, Nannan Xu, Jia Liu, Zhenzhen Chen, Xu Liu, Junnan Wang

    Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. Recent studies have shown that n6-methyladenosine (m6A) plays a major role in cardiovascular homeostasis and pathophysiology. These studies have confirmed that m6A methylation affects the pathophysiology of cardiovascular diseases by regulating cellular processes such as differentiation, proliferation, inflammation, autophagy, and apoptosis. Moreover, plenty of research has confirmed that m6A modification can delay the progression of CVD via the post-transcriptional regulation of RNA. However, there are few available summaries of m6A modification regarding CVD. In this review, we highlight advances in CVD-specific research concerning m6A modification, summarize the mechanisms underlying the involvement of m6A modification during the development of CVD, and discuss the potential of m6A modification as a therapeutic target of CVD.


  • Open Access

    The Role of Ferroptosis in Cardiovascular Disease and Its Therapeutic Significance

    by Zhenzhen Chen, Youyou Yan, Chao Qi, Jia Liu, Longbo Li, Junnan Wang

    Cardiovascular diseases (CVDs) are the leading cause of deaths worldwide with regulated cell death playing an important role in cardiac pathophysiology. However, the classical mode of cell death cannot fully explain the occurrence and development of heart disease. In recent years, much research has been performed on ferroptosis, a new type of cell death that causes cell damage and contributes to the development of atherosclerosis, myocardial infarction, heart failure, and other diseases. In this review, we discuss the role of different organelles in ferroptosis and also focus on the relationship between autophagy and ferroptosis. Additionally, we describe the specific mechanism by which ferroptosis contributes to the development of CVD. Finally, we summarize the current research on ferroptosis-related pathway inhibitors and the applications of clinically beneficial cardiovascular drugs.


  • Open Access

    Protocol for the Acute Myocardial Infarction Study in Northeastern China (AMINoC): a real-world prospective cohort study

    by Tianyi Li, Junduo Wu, Jia Liu, Wei Sun, Chao Qi, Bin Liu, George A Wells, Junnan Wang

    Introduction Acute myocardial infarction (AMI) has become one of the major causes of mortality and morbidity in China. However, little is known about the characteristics, medical care and outcomes of patients with AMI in Northeastern China. The Acute Myocardial Infarction Study in Northeastern China (AMINoC) is aimed at obtaining timely real-world knowledge in terms of characteristics, clinical care and outcomes of patients with AMI and at providing care-quality improvement efforts in Northeastern China. Methods and analysis The AMINoC is a real-world, prospective, multicentre cohort study. The study selected 20 hospitals using stratified cluster sampling from different levels of hospitals among nine districts throughout Jilin Province. Hospitalised patients with a primary diagnosis of AMI in each site are consecutively enrolled for 1 year. Demographic characteristics, clinical data, treatments, outcomes and cost are collected by local investigators. Patient follow-up after discharge is planned for up to 2 years. Ethics and dissemination The protocol has been approved by the ethics committee at the Second Hospital of Jilin University. The findings of this study will be published in peer-reviewed journals and medical conferences. Trial registration NCT04451967.